The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...
FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research ...
Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers (pMDIs) to dry powder inhalers (DPIs) and vice versa.
Distinct patterns of symptom severity among patients with COPD sheds light on the heterogeneous nature of the patients’ ...
N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.
Researchers at Karolinska Institutet and the University of Gothenburg have identified a biomarker that could become an ...
A rapid decline in lung function is linked to the development of chronic obstructive pulmonary disease (COPD) ...
Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects ...
A study by doctoral student Adriana Eugene and Distinguished Professor Luisa N. Borrell found that older adults who use ...
The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
Data support Ohtuvayreâ„¢ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...